NEW YORK, March 13, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Amit Sharma, M.D. to the newly created position of Vice President, Medical Affairs.
Amit Sharma, M.D., is an accomplished board certified nephrologist, internist, and hypertension specialist who has a broad-based background in chronic kidney disease and dialysis. Recently, Dr. Sharma was Medical Director, Medical Affairs, at Reata Pharmaceuticals. From 2005-2012, Dr. Sharma served as a Medical Director and Senior Advisor for Liberty Dialysis, LLC, a medium-size dialysis organization with over 300 dialysis clinics. Liberty was sold in 2011 to Fresenius Medical Care AG for $1.7 billion. From 2001 to 2005, Dr. Sharma served as the Director of the Dialysis Unit and of the Chronic Kidney Disease Clinic for the Naval Medical Center, San Diego.
Dr. Sharma received his medical degree from Louisiana State University Medical Center-New Orleans. He completed his fellowship in Nephrology and Hypertension from University of California in San Diego in 2001. Dr. Sharma also has extensive experience conducting primary research and as a principal investigator for numerous clinical trials in the field of nephrology and hypertension. He has published in many respected peer reviewed journals and he is a well known presenter for national and international meetings.
Ron Bentsur, the Company's Chief Executive Officer, commented, "We are thrilled to welcome Dr. Sharma to Keryx. Dr. Sharma has a prominent national reputation and a proven track record of success within the dialysis community. I believe that Dr. Sharma's vast knowledge and experience of dialysis care will be particularly invaluable to the Company as we continue to expand our presence in this field."Dr. Sharma stated, "I am excited to be joining Keryx. I view Zerenex to be a uniquely attractive compound that can potentially alter current practice patterns with the ultimate aim of improving the lives of dialysis and chronic kidney disease patients worldwide. I look forward to applying my nephrology and dialysis expertise to contribute towards the success of Zerenex."